Ivy Capital Research
Investment Thesis
Ivy Capital (常春藤资本, also styled 常春藤投资) is a Shanghai-headquartered venture capital firm founded in 2007. The firm's stated philosophy, taken directly from its own site, is "the true value in value investing is technology" — the partnership frames its edge as spotting genuine technological value beneath market noise and short-term hype cycles. Ivy Capital has built an 18-year track record as a boutique, historically-rooted VC concentrated on the Yangtze River Delta economic corridor, with secondary coverage of Beijing and Guangzhou. The firm invests across both enterprise services and deep technology, and manages parallel RMB and USD-denominated vehicles, giving it flexibility to back both domestic-listing-track companies and globally-oriented startups.
Sector Focus
The portfolio spans a wide sector footprint, consistent with a generalist early-stage China VC with a tilt toward enterprise and deep tech:
- Enterprise applications and vertical SaaS
- High-tech / deep tech (AI, computer vision, VR/AR hardware)
- Consumer and retail
- Healthcare and pharmaceutical platforms (digital pharmacy / internet hospital models)
- Media, content protection, and AI-generated video/entertainment
- Robotics and industrial automation
Recent 2026 activity shows the firm leaning further into frontier AI, participating in the Series C extension of Aishi Technology's PixVerse, a generative AI video/world-model platform.
Stage Focus
Ivy Capital is primarily a Series A investor, with meaningful activity at Seed and Series B as well. Aggregated deal data (Tracxn, PitchBook) shows the bulk of the 108+ company portfolio entering at Series A, with growth-stage follow-ons for standout performers (e.g., Bob/HiBob at Series D, PixVerse at Series C).
Check Size
The firm does not publish specific check-size ranges on its own site, and no reliable range could be confirmed from secondary sources. Given a ~$800M-equivalent AUM against 130+ portfolio companies, typical initial checks are likely in the single-digit millions (USD-equivalent), consistent with a Series A-led China VC, but this should be treated as directional rather than confirmed.
Lead Tendency
Evidence is mixed. In its most recent identifiable deal (PixVerse's 2026 Series C extension), Ivy Capital was one of eight-plus participating investors in a round led by Alibaba — a follower position. Historical data does not provide enough named lead-investor confirmations to generalize, so lead tendency is best classified as unknown pending deeper diligence on individual rounds.
Recent Activity
- July 2026: Participated (as new investor) in the Series C extension of Aishi Technology / PixVerse, a Chinese AI video-generation and world-model startup, alongside Alibaba (lead), Mirae Asset, Eastern Bell Capital, BlueFocus, CloudAlpha, and others. The extension brought total Series C proceeds to $439M and pushed valuation past $2B.
- The firm's own site lists 130+ invested companies to date and over 6 billion RMB (~$830M USD equivalent) in equity AUM, with both RMB and USD fund vehicles active.
Fund status could not be confirmed as actively raising a new numbered fund from public sources at this time, but the 2026 PixVerse participation indicates the firm is actively deploying capital.
Portfolio Highlights
- Bob (HiBob) — HR/payroll/finance platform, reached Series D with $574M total funding; one of the portfolio's headline outcomes.
- PixVerse (Aishi Technology) — AI video generation and "world model" platform; Series C extension closed July 2026 at $2B+ valuation, 150M+ users across 177+ countries.
- Pimax — VR headset manufacturer, Series C, $82.7M total funding; one of the earliest independent VR hardware makers out of China to reach global distribution.
- Vobile — Digital content fingerprinting / rights-protection platform (VDNA technology), publicly listed (Hong Kong), headquartered in Silicon Valley with Hong Kong and Tokyo offices.
- 111 Group / 111 Inc. (1药网) — Internet pharmacy and digital healthcare platform, NASDAQ-listed (YI) following its US IPO.
- Anagog — Israel-based mobility/location-data platform, Series C.
- The disclosed exit record includes 1 unicorn, roughly 10-11 IPOs (including RobotPhoenix and Taimei Technology), and several acquisitions.
Team
Ivy Capital's team is organized as a multi-partner partnership (reported at ~16-22 professionals including 8-12 partners across sources, reflecting some data staleness between aggregators). Named partners identified across public sources:
- Fu Lei — Founding Partner
- Weng Jiyi — Founding Partner
- Du Yue (Alan Du) — Partner
- Huizhong Fan — Partner
- Frank Donghai Yin — Partner
- Lu Ming — Partner
- Charles Huang — Partner (noted in secondary sources)
The firm's own website content is served primarily in Chinese and includes a formal fraud-warning notice about impersonators soliciting business plans through unauthorized channels — worth flagging for outreach hygiene (verify any inbound "Ivy Capital" contact against the official [email protected] / [email protected] addresses).
Decision Process
Structured as a multi-partner partnership rather than a solo-GP shop, consistent with its 8-12 named partners and offices across Shanghai, Beijing, Hangzhou, and Hong Kong. No public detail on committee structure or timeline was available.
Founder Preferences
The firm's public description emphasizes backing companies with "defensible business models, strong management teams, and huge market potential" — a classic quality-over-narrative filter typical of a long-tenured, regionally-embedded China growth investor rather than a thesis-driven frontier fund, even as its 2026 activity (PixVerse) shows willingness to chase category-defining AI outcomes.
Geographic Focus
Primary focus is Mainland China, concentrated in the Yangtze River Delta (Shanghai, Hangzhou, and surrounding Jiangsu/Zhejiang cities) with secondary coverage of Beijing and Guangzhou. Portfolio data shows the large majority of investments in China, with a minority footprint in the United States, South Korea, Israel, and Singapore — reflecting occasional cross-border co-investment (e.g., Anagog in Israel, participation in the PixVerse round alongside Korea's Mirae Asset).
Headquarters and Contact
Headquartered at Pudong Kerry Centre, 38th Floor, 1155 Fangdian Road, Pudong New Area, Shanghai. Additional offices reported in Beijing, Hangzhou, and Hong Kong. General phone: 021-61908961. HR inquiries: [email protected]. Business plan submissions: [email protected].